Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer

About this trial
This is an interventional treatment trial for Recurrent Non-Small Cell Lung Carcinoma
Eligibility Criteria
Inclusion Criteria:
- Patients must have the psychological ability and general health that permits completion of the study requirements and required follow up
- Women of childbearing potential and men who are sexually active should be willing and able to use medically acceptable forms of contraception during the trial and for up to 180 days after completion of all treatment to prevent pregnancy or fathering a child.
- Pathologically proven diagnosis of NSCLC, with metastases (stage IV disease) present prior to registration; this includes patients newly diagnosed with metastatic disease or those initially diagnosed and treated for stage I-III NSCLC who ultimately develop metastases
Appropriate stage for study entry based on the following diagnostic workup:
- History/physical examination within 30 days prior to registration
- Imaging proof of limited metastatic disease and response to therapy/stable disease, by at least CT chest through the adrenals or PET/CT within 30 days prior to registration
- Zubrod performance status 0, 1, or 2 within 30 days prior to registration
- Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 × upper limit of normal (ULN) or ≤ 5 × ULN with metastatic liver disease
- Total bilirubin ≤ 1.5 × ULN
- Absolute neutrophil count (ANC) ≥ 500 cells/mm^3
- Creatinine clearance ≥ 45 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
- Platelets ≥ 50,000 cells/mm^3
- Negative serum pregnancy test within one week prior to registration for females of childbearing potential
- Patients must have received first-line/induction chemotherapy (4 cycles) and achieved stable disease or a partial response
- Prior systemic chemotherapy as part of concurrent treatment approach for previously diagnosed stage III NSCLC, as adjuvant therapy for previously resected NSCLC, or for other previous cancers is permitted
- Prior radiotherapy for patients with brain metastases prior to enrollment is acceptable
- Patients must have measurable disease at baseline and 3 or fewer discrete, extracranial metastatic disease sites that are technically amenable to SBRT
- For de novo stage IV NSCLC patients (patients with metastatic disease at first presentation), primary disease must be treatable with local therapy in the form of SBRT or hypofractionated radiation; if the primary disease is found in the peripheral or central lung parenchyma without nodal disease for instance, SBRT may be employed; if primary disease is more advanced with involvement of the mediastinum (T4 tumor, N1-N3 disease, etc.), these volumes should be technically treatable with hypofractionated radiation
- If primary disease in the thoracic cavity was previously treated with local therapy in the form of surgery, any local/regional disease recurrence should be technically treatable with SBRT or hypofractionated radiation after induction systemic therapy
- Patients must be registered within 35 days of administration of the last dose of first-line/induction systemic therapy
- The patient or a legally authorized representative must provide study-specific informed consent prior to study entry
- Patients with brain metastases are eligible if these lesions have been previously treated and the patients have no clinical or radiographic evidence of progression prior to enrollment
Exclusion Criteria:
- Clinical or radiologic evidence of untreated and/or progressive brain metastases
- Cutaneous metastasis of NSCLC
- Metastatic disease invading the esophagus, stomach, intestines, or mesenteric lymph nodes if not a candidate for surgery for these lesions
- Prior invasive malignancy (except non-melanomatous skin cancer, low or intermediate risk prostate cancer, or in situ carcinoma of breast, oral cavity, skin, or cervix) unless disease free for a minimum of one year
Metastases located within 3 cm of previously irradiated (< 3Gy per fraction) structures if if not a candidate for surgery for these lesions and if:
- Spinal cord previously irradiated to > 40 Gy
- Brachial plexus previously irradiated to > 50 Gy
- Small intestine, large intestine, or stomach previously irradiated to > 45 Gy
- Brainstem previously irradiated to > 50 Gy
- Lung previously irradiated with prior V20 Gy > 35%
- Patients receiving targeted therapy (non-cytotoxic systemic therapy) for NSCLC in the first-line setting
- If a patient has progressed in previous areas of primary disease that received definitive doses of radiation, these patients would require re-irradiation in previous high dose anatomic areas and are not eligible for this study
- Patients with malignant pleural effusions that do not resolve after first-line systemic therapy; patients with pleural effusions that have become too small for thoracentesis at the time of registration would be permitted on study, indicating a significant response to first-line chemotherapy
- Patients with more than 3 discrete locations of extra-cranial metastatic disease after first-line systemic therapy requiring more than 3 SBRT plans to cover these distinct metastatic disease entities
- Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
- Patients who are pregnant or nursing
- Participation in any investigational drug study (excluding non-oncology and/or symptom management studies) within 4 weeks prior to registration
- Known human immunodeficiency virus (HIV) positive with cluster of differentiation 4 (CD4) count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count ≥ 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol
- For patients who received immunotherapy during induction, patients on chronic steroids or who have active autoimmune disease for which they received systemic treatment in the previous 2 years with corticosteroids, disease modifying agents, or immunosuppressive drugs are not eligible. Replacement therapy (thyroxine, insulin or physiological corticosteroid replacement for adrenal or pituitary insufficiency) is allowed. Patients with active interstitial lung disease or who have a history of pneumonitis for which they had received glucocorticoids are not eligible
- Prior bevacizumab therapy or other antiangiogenic therapy in first-line or planned maintenance therapy (due to potential for increased complications from local therapy)
Sites / Locations
- University of Alabama at Birmingham Cancer Center
- Arizona Breast Cancer Specialists-Gilbert
- Arizona Center for Cancer Care-Peoria
- Mayo Clinic Hospital in Arizona
- Arizona Breast Cancer Specialists-Scottsdale
- Mayo Clinic in Arizona
- University of Arizona Cancer Center-Orange Grove Campus
- Banner University Medical Center - Tucson
- University of Arizona Cancer Center-North Campus
- University of Arkansas for Medical Sciences
- Alta Bates Summit Medical Center-Herrick Campus
- City of Hope Comprehensive Cancer Center
- UC San Diego Moores Cancer Center
- Los Angeles County-USC Medical Center
- USC / Norris Comprehensive Cancer Center
- Memorial Medical Center
- Saint Joseph Hospital - Orange
- The Permanente Medical Group-Roseville Radiation Oncology
- Sutter Medical Center Sacramento
- University of California Davis Comprehensive Cancer Center
- Saint Helena Hospital
- Salinas Valley Memorial
- City of Hope South Pasadena
- Kaiser Permanente Cancer Treatment Center
- Gene Upshaw Memorial Tahoe Forest Cancer Center
- Penrose-Saint Francis Healthcare
- UCHealth Memorial Hospital Central
- Porter Adventist Hospital
- Poudre Valley Hospital
- Yale University
- Helen F Graham Cancer Center
- Beebe Health Campus
- UM Sylvester Comprehensive Cancer Center at Coral Gables
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
- University of Florida Health Science Center - Gainesville
- Mayo Clinic in Florida
- University of Miami Miller School of Medicine-Sylvester Cancer Center
- Miami Cancer Institute
- UM Sylvester Comprehensive Cancer Center at Kendall
- Orlando Health Cancer Institute
- UM Sylvester Comprehensive Cancer Center at Plantation
- Tallahassee Memorial HealthCare
- Moffitt Cancer Center
- Cleveland Clinic-Weston
- Grady Health System
- Emory University Hospital Midtown
- Emory University Hospital/Winship Cancer Institute
- Emory Saint Joseph's Hospital
- Augusta University Medical Center
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
- Queen's Medical Center
- The Cancer Center of Hawaii-Liliha
- Saint Alphonsus Medical Center-Nampa
- Northwestern University
- Rush University Medical Center
- University of Illinois
- Decatur Memorial Hospital
- Crossroads Cancer Center
- Western Illinois Cancer Treatment Center
- Edward Hines Jr VA Hospital
- Condell Memorial Hospital
- Loyola University Medical Center
- Advocate Lutheran General Hospital
- Methodist Medical Center of Illinois
- OSF Saint Francis Medical Center
- SwedishAmerican Regional Cancer Center/ACT
- Memorial Medical Center
- Southwest Illinois Health Services LLP
- Carle Cancer Center
- Parkview Hospital Randallia
- Parkview Regional Medical Center
- Goshen Center for Cancer Care
- Community Cancer Center East
- Community Cancer Center South
- Franciscan Health Indianapolis
- Community Cancer Center North
- Franciscan Health Mooresville
- Mercy Cancer Center-West Lakes
- Iowa Methodist Medical Center
- Mercy Medical Center - Des Moines
- University of Kansas Cancer Center
- Lawrence Memorial Hospital
- University of Kansas Cancer Center-Overland Park
- Ascension Via Christi Hospitals Wichita
- Saint Elizabeth Medical Center South
- University of Kentucky/Markey Cancer Center
- Norton Hospital Pavilion and Medical Campus
- The James Graham Brown Cancer Center at University of Louisville
- Norton Brownsboro Hospital and Medical Campus
- LSU Health Baton Rouge-North Clinic
- Louisiana Hematology Oncology Associates LLC
- Mary Bird Perkins Cancer Center
- Our Lady of the Lake Physicians Group - Medical Oncology
- University of Maryland/Greenebaum Cancer Center
- Central Maryland Radiation Oncology in Howard County
- UM Baltimore Washington Medical Center/Tate Cancer Center
- TidalHealth Richard A Henson Cancer Institute
- TidalHealth Peninsula Regional
- Massachusetts General Hospital Cancer Center
- Brigham and Women's Hospital
- Boston Medical Center
- Lahey Hospital and Medical Center
- McLaren Cancer Institute-Bay City
- McLaren Cancer Institute-Clarkston
- Henry Ford Macomb Hospital-Clinton Township
- Wayne State University/Karmanos Cancer Institute
- Henry Ford Hospital
- Ascension Saint John Hospital
- Weisberg Cancer Treatment Center
- McLaren Cancer Institute-Flint
- Singh and Arora Hematology Oncology PC
- Allegiance Health
- West Michigan Cancer Center
- McLaren-Greater Lansing
- Mid-Michigan Physicians-Lansing
- Sparrow Hospital
- McLaren Cancer Institute-Lapeer Region
- Saint Mary Mercy Hospital
- McLaren Cancer Institute-Macomb
- McLaren Cancer Institute-Northern Michigan
- 21st Century Oncology-Pontiac
- McLaren-Port Huron
- William Beaumont Hospital-Royal Oak
- Ascension Saint Mary's Hospital
- William Beaumont Hospital - Troy
- Saint John Macomb-Oakland Hospital
- Metro Health Hospital
- Sanford Joe Lueken Cancer Center
- Saint Luke's Hospital of Duluth
- Hennepin County Medical Center
- Coborn Cancer Center at Saint Cloud Hospital
- Regions Hospital
- Saint Francis Medical Center
- Siteman Cancer Center at West County Hospital
- Kansas City Veterans Affairs Medical Center
- Delbert Day Cancer Institute at PCRMC
- Washington University School of Medicine
- Missouri Baptist Medical Center
- Mercy Hospital Saint Louis
- Mercy Hospital Springfield
- Saint James Community Hospital and Cancer Treatment Center
- Benefis Healthcare- Sletten Cancer Institute
- Kalispell Regional Medical Center
- Nebraska Methodist Hospital
- Alegent Health Bergan Mercy Medical Center
- Renown Regional Medical Center
- Wentworth-Douglass Hospital
- Dartmouth Hitchcock Medical Center
- Memorial Sloan Kettering Basking Ridge
- Memorial Sloan Kettering Monmouth
- Memorial Sloan Kettering Bergen
- Virtua Samson Cancer Center
- Virtua Memorial
- Community Medical Center
- Virtua Voorhees
- Lovelace Medical Center-Saint Joseph Square
- University of New Mexico Cancer Center
- Lovelace Radiation Oncology
- Christus Saint Vincent Regional Cancer Center
- Montefiore Medical Center-Einstein Campus
- Montefiore Medical Center - Moses Campus
- New York-Presbyterian/Brooklyn Methodist Hospital
- Memorial Sloan Kettering Commack
- Memorial Sloan Kettering Westchester
- Mount Sinai West
- Mount Sinai Hospital
- Memorial Sloan Kettering Cancer Center
- University of Rochester
- Stony Brook University Medical Center
- State University of New York Upstate Medical University
- Memorial Sloan Kettering Nassau
- Dickstein Cancer Treatment Center
- Carolinas Medical Center/Levine Cancer Institute
- Atrium Health Pineville/LCI-Pineville
- Atrium Health University City/LCI-University
- Atrium Health Cabarrus/LCI-Concord
- Duke University Medical Center
- Atrium Health Union/LCI-Union
- CarolinaEast Medical Center
- NHRMC Radiation Oncology - Supply
- New Hanover Regional Medical Center/Zimmer Cancer Center
- NHRMC Radiation Oncology - 16th Street
- Sanford Bismarck Medical Center
- Sanford Roger Maris Cancer Center
- Altru Cancer Center
- Cleveland Clinic Akron General
- UHHS-Chagrin Highlands Medical Center
- Geauga Hospital
- Adena Regional Medical Center
- University of Cincinnati Cancer Center-UC Medical Center
- Case Western Reserve University
- Cleveland Clinic Cancer Center/Fairview Hospital
- Cleveland Clinic Foundation
- Ohio State University Comprehensive Cancer Center
- The Mark H Zangmeister Center
- Cleveland Clinic Cancer Center Mansfield
- Hillcrest Hospital Cancer Center
- UH Seidman Cancer Center at Lake Health Mentor Campus
- UH Seidman Cancer Center at Southwest General Hospital
- University Hospitals Parma Medical Center
- University Hospitals Portage Medical Center
- North Coast Cancer Care
- UH Seidman Cancer Center at Firelands Regional Medical Center
- ProMedica Flower Hospital
- University of Cincinnati Cancer Center-West Chester
- UH Seidman Cancer Center at Saint John Medical Center
- UHHS-Westlake Medical Center
- Cleveland Clinic Wooster Family Health and Surgery Center
- Genesis Healthcare System Cancer Care Center
- University of Oklahoma Health Sciences Center
- Mercy Hospital Oklahoma City
- Good Samaritan Hospital
- Legacy Mount Hood Medical Center
- Legacy Good Samaritan Hospital and Medical Center
- Providence Portland Medical Center
- Providence Saint Vincent Medical Center
- Bryn Mawr Hospital
- Geisinger Medical Center
- Delaware County Memorial Hospital
- Northeast Radiation Oncology Center
- UPMC Pinnacle Cancer Center/Community Osteopathic Campus
- Penn State Milton S Hershey Medical Center
- Lancaster General Ann B Barshinger Cancer Institute
- Lancaster General Hospital
- Geisinger Medical Oncology-Lewisburg
- Lewistown Hospital
- Paoli Memorial Hospital
- Thomas Jefferson University Hospital
- Fox Chase Cancer Center
- Jefferson Torresdale Hospital
- Geisinger Cancer Services-Pottsville
- Guthrie Medical Group PC-Robert Packer Hospital
- Reading Hospital
- Geisinger Wyoming Valley/Henry Cancer Center
- Asplundh Cancer Pavilion
- Lankenau Medical Center
- Prisma Health Cancer Institute - Spartanburg
- Prisma Health Cancer Institute - Faris
- Saint Francis Cancer Center
- Prisma Health Cancer Institute - Eastside
- Self Regional Healthcare
- Prisma Health Cancer Institute - Greer
- Gibbs Cancer Center-Pelham
- The Radiation Oncology Center-Hilton Head/Bluffton
- Prisma Health Cancer Institute - Seneca
- Spartanburg Medical Center
- Sanford USD Medical Center - Sioux Falls
- Baptist Memorial Hospital and Cancer Center-Memphis
- UT Southwestern/Simmons Cancer Center-Dallas
- UT Southwestern/Simmons Cancer Center-Fort Worth
- University of Texas Medical Branch
- M D Anderson Cancer Center
- Covenant Medical Center-Lakeside
- University of Texas Health Science Center at San Antonio
- Huntsman Cancer Institute/University of Utah
- George E Wahlen Department of Veterans Affairs Medical Center
- Norris Cotton Cancer Center-North
- VCU Massey Cancer Center at Stony Point
- Virginia Commonwealth University/Massey Cancer Center
- Legacy Salmon Creek Hospital
- West Virginia University Healthcare
- Langlade Hospital and Cancer Center
- Ascension Saint Elizabeth Hospital
- Aurora Cancer Care-Southern Lakes VLCC
- Marshfield Medical Center-EC Cancer Center
- Aurora Health Center-Fond du Lac
- Aurora Health Care Germantown Health Center
- Aurora Cancer Care-Grafton
- Saint Vincent Hospital Cancer Center Green Bay
- Saint Vincent Hospital Cancer Center at Saint Mary's
- Aurora BayCare Medical Center
- Aurora Cancer Care-Kenosha South
- Gundersen Lutheran Medical Center
- Aurora Bay Area Medical Group-Marinette
- Marshfield Medical Center-Marshfield
- Froedtert Menomonee Falls Hospital
- Aurora Cancer Care-Milwaukee
- Aurora Saint Luke's Medical Center
- Medical College of Wisconsin
- Aurora Sinai Medical Center
- Marshfield Clinic-Minocqua Center
- Ascension Mercy Hospital
- Vince Lombardi Cancer Clinic - Oshkosh
- Aurora Cancer Care-Racine
- Vince Lombardi Cancer Clinic-Sheboygan
- Marshfield Clinic Stevens Point Center
- Aurora Medical Center in Summit
- Vince Lombardi Cancer Clinic-Two Rivers
- Aspirus Regional Cancer Center
- Aurora Cancer Care-Milwaukee West
- Aurora West Allis Medical Center
- Froedtert West Bend Hospital/Kraemer Cancer Center
- Marshfield Medical Center - Weston
- Aspirus Cancer Care - Wisconsin Rapids
- Cross Cancer Institute
- London Regional Cancer Program
- Ottawa Hospital and Cancer Center-General Campus
- Chaim Sheba Medical Center
- King Faisal Specialist Hospital and Research Centre
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Arm 1 (maintenance chemotherapy)
Arm 2 (SBRT + maintenance chemotherapy)
Patients may receive docetaxel IV over 60 minutes on day 1, erlotinib hydrochloride PO QD, or gemcitabine IV over 30 minutes on days 1 and 8. Patients with non-squamous non-small cell lung cancer may receive pemetrexed disodium IV over 10 minutes on day 1 alone or in combination with pembrolizumab IV over 30 minutes. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Patients undergo LCT over 2-4 weeks. If LCT cannot be used to treat primary disease sites, patients also undergo IMRT or 3DCRT over 3-5 weeks. Within 2 weeks after completion of radiation therapy, patients receive chemotherapy as in Arm 1. Patients may possibly undergo surgery.